Mirum Pharmaceuticals, Inc.
MIRM
Rang in Aktien
#3254
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aktienkurs
$83.62
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$5.43B
Veränderung (1 Tag)
-1.71%
Veränderung (1 Jahr)
20.14%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategorie
Healthcare
Kursverlauf für Mirum Pharmaceuticals, Inc. (MIRM)
Höchster Schlusskurs: $82.31 am 2026-10-01
Niedrigster Schlusskurs: $13.66 am 2019-07-01
Niedrigster Schlusskurs: $13.66 am 2019-07-01
Kursverlauf der Aktie von Mirum Pharmaceuticals, Inc. von 2019 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 28.91% |
| 2025 | 68.24% |
| 2024 | 35.06% |
| 2023 | 73.09% |
| 2022 | 24.19% |
| 2021 | -29.47% |
| 2020 | 29.71% |
| 2019 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.16 | -4.25% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
